Is Apelix a PI3K inhibitor?

Alpelisibis a αspecificI class pan>PI3K inhibitors which inhibit the phosphorylation of downstream PI3K target proteins (including AKT) and also inhibit PIK3CAGrowth of mutated breast cancer cell lines in vitro and in vivo, Alpelisib(Alpelisib< span>)Used in combination with fulvestrant (Faslodex) to treat certain types of breast cancer that have spread to nearby tissue or other parts of the body in women who have gone through menopause or in men whose cancer has worsened during or after menstruation.

In the BYLieve study, the percentage of patients alive without disease progression at 6 months was 50.4%in cohort A (< For patients who progressed on CDK4/6 and ET and received fulvestrant-containing apricoxib), the percentage of patients alive and free of disease progression at 6 months was 48.7%. The pharmacokinetics of Apelix® have been studied in healthy subjects and adult patients with solid tumors. Under fed conditions, between 30 mg and 450 mg dose range (0.1 to 1.5 times the approved recommended dose), The steady-state maximum plasma concentration of apelix (Cmax) and AUC increase proportionally. The average accumulation of apelix ranges from 1.3 to 1.5 and steady-state plasma concentrations are reached within 3 days after daily dosing. Population-based approach in adult patients receiving PIQRAY 300 mg once daily in the SOLAR-1 trialThe average steady-state Cmaxalpelisib[coefficient of variation (CV%)] is 2480 (23%< span>)ng/mL, AUC0-24hr is 33224 (21%)ng * h/mL. The retail price of the Indian version of the original medicine in pharmacies150mg28 is around three to four thousand per pill. The retail price of the European version in pharmacies is about 150mg56 tablets4 about 10,000 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0